HIKAL Hikal Q4 FY26 results (Jan–Mar 2026) and concall
Hikal reported a strong Q4 FY26 with revenue of INR 519 crores and EBITDA margins of 20.3%, driven by recovery in both Pharma and Crop Protection segments. However, the full year FY26 saw negative PBT due to significant exceptional items, including an impairment charge and new labour code costs. The company is actively addressing FDA compliance issues and expects a return to growth in FY27, leveraging strategic investments in CDMO and Animal Health.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue down 6.0%, net profit down 71.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 453 | 448 | 552 | 380 | 319 −30% | 494 +10% | 519 −6% |
| EBITDA | 75 | 72 | 123 | 25 | 7 −90% | 83 +15% | 105 −15% |
| Net profit | 18 | 17 | 50 | -22 | -35 −291% | -6 −134% | 14 −71% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
